• Mary Joy Samidoss
• Dr. Victor Arokia Doss

Depression is a potentially life-threatening disorder in worldwide. Depression a mental health disorder characterized by persistent depressed mood or loss of interest in activities, causing daily life to be significantly impaired. Deprivation of glucose in energy metabolism of brain leads to depression. To overcome this reduction of glucose in brain, lactate is significantly impaired with energy metabolism of brain. Monocarboxylate transporters [MCTs] have a high capacity for transporting short-chain monocarboxylates, such as lactate, Pyruvate and the ketone bodies through blood brain barriers. MCT1, MCT2, and MCT 4 have contributed to the emergence of the physiological concept of intercellular lactate shuttle. Lactate shuttle sources of distress include potential triggers. Increasingly, activation of certain neural circuits in the brain can trigger changes in brain function. . This hypothesis can help to elucidate the surprisingly positive results found in the treatment of depression with lactate shuttle. Psychological and pharmacological therapy, or a mixture of both, is typically the primary basis of treatment. Research is increasingly suggesting that these treatments can normalise depression-related brain changes.

Depression, monocarboxylate transporters (MCTs), Lactate shuttle

"DEPRESSION: AN OVERVIEW IN THE PATHOPHYSIOLOGY AND TREATMENT", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.8, Issue 3, page no.982-991, March-2021, Available :http://www.jetir.org/papers/JETIR2103134.pdf

"DEPRESSION: AN OVERVIEW IN THE PATHOPHYSIOLOGY AND TREATMENT", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.8, Issue 3, page no. pp982-991, March-2021, Available at : http://www.jetir.org/papers/JETIR2103134.pdf